Writing group disclosures
| Writing group member | Employment | Research grant | Other research support | Speakers’ bureau/honoraria | Expert witness | Ownership interest | Consultant/advisory board | Other |
|---|---|---|---|---|---|---|---|---|
| Caroline S. Fox | NHLBI | None | None | None | None | None | None | None |
| Sherita Hill Golden | Johns Hopkins University | NIH† | None | None | None | None | None | None |
| Cheryl Anderson | University of California at San Diego | None | None | None | None | None | None | None |
| George A. Bray | Pennington Biomedical Research Center | NIH† | None | Takeda* | None | None | Novo-Nordisk*; Herbalife*; Medifast* | NIH† |
| Lora E. Burke | University of Pittsburgh | NIH† | None | None | None | None | None | NHLBI† |
| Ian H. de Boer | University of Washington | Abbvie†; Medtronic* | None | None | None | None | Bayer*; Amgen* | None |
| Prakash Deedwania | UCSF Fresno Program | None | None | None | None | None | None | None |
| Robert H. Eckel | University of Colorado | Janssen† | None | None | None | None | Janssen*; Regeneron†; Sanofi† | Janssen* |
| Abby G. Ershow | NIH Office of Dietary Supplements | None | None | None | None | Johnson & Johnson† | None | None |
| Judith Fradkin | NIH/NIDDK | None | None | None | None | None | None | NIH/NIDDK† |
| Silvio E. Inzucchi | Yale University School of Medicine | Takeda† | None | None | Pfizer*; Takeda* | None | Boehringer Ingelheim†; AstraZeneca*; Merck*; Novo Nordisk*; Regeneron*; Janssen* | None |
| Mikhail Kosiborod | Mid America Heart Institute | Gilead†; Genentech†; Sanofi Aventis†; Eisai†; AstraZeneca† | Gilead† | None | None | None | AstraZeneca†; Eli Lilly*; Regeneron*; Roche*; Gilead*; Amgen†; Takeda*; Edwards Lifesciences*; Glytec*; GSK*; ZS Pharma† | None |
| Robert G. Nelson | National Institutes of Health | None | None | None | None | None | None | None |
| Mahesh J. Patel | Merck Research Laboratories | None | None | None | None | None | None | Merck Research Laboratories† |
| Michael Pignone | University of North Carolina | None | None | None | None | None | None | None |
| Laurie Quinn | University of Illinois at Chicago | None | None | None | None | None | None | None |
| Philip R. Schauer | Cleveland Clinic | STAMPEDE Trial†; ARMMS Trial† | None | None | None | SE Quality Healthcare Consulting†; SurgiQuest* | Ethicon*; Nestle*; Intuitive* | None |
| Elizabeth Selvin | Johns Hopkins Bloomberg School of Public Health | NIH/NIDDK† | None | None | None | None | None | None |
| Dorothea K. Vafiadis | American Heart Association | None | None | None | None | None | None | None |
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*
Modest.
†
Significant.